Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01)

BACKGROUND: A randomized trial of vinorelbine plus gemcitabine followed by docetaxel (VGD) versus paclitaxel plus carboplatin (PC) in patients with advanced non-small-cell lung cancer showed no difference in overall survival (median survival time: 13.6 versus 14.1 months) between the two treatment g...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kawahara, Masaaki, Tada, Harue, Tokoro, Akihiro, Teramukai, Satoshi, Origasa, Hideki, Kubota, Kaoru, Shinkai, Tetsu, Fukushima, Masanori, Furuse, Kiyoyuki
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2011
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3179458/
https://ncbi.nlm.nih.gov/pubmed/21849041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-356
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items